RedHill Biopharma Ltd. (RDHL)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study.
RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Country | IL |
IPO Date | Jan 7, 2013 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 53 |
CEO | Dror Ben-Asher |
Contact Details
Address: 21 Ha’arba’a Street Tel Aviv, IL | |
Website | https://www.redhillbio.com |
Stock Details
Ticker Symbol | RDHL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001553846 |
CUSIP Number | 757468103 |
ISIN Number | US7574682024 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dror Ben-Asher | Co-Founder, Chairman & Chief Executive Officer |
Gilead Raday MPhil, MSc | Chief Operating Officer |
Razi Ingber | Chief Financial Officer |
Adi Frish | Chief Corporate & Business Development Officer |
Alexandra Okmian | Senior Business Development & Investor Relations Manager |
Dr. Reza Fathi Ph.D. | Senior Vice President of Research & Development |
Guy Goldberg J.D. | Chief Business Officer |
Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs |
Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. & Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 21, 2025 | 6-K | Filing |
Dec 10, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 28, 2024 | 6-K | Filing |
Oct 22, 2024 | 6-K | Filing |
Oct 15, 2024 | 6-K | Filing |
Oct 01, 2024 | 6-K | Filing |
Sep 30, 2024 | 6-K | Filing |
Sep 18, 2024 | 6-K | Filing |